RxDoctor Payments DataLook up a doctor →

Takkin Lo, MD

Pulmonary Disease · Honolulu, HINPI 1942221742

Payments from drug & device makers

$324,215in general payments, 2019–2025

Across 658 payments — averaging $492.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$205K
  • AstraZeneca$55K
  • Boehringer Ingelheim$48K
  • Insmed, Inc.$14K
  • Johnson & Johnson$642
  • Sanofi$280
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$11,1703%
  • Speaking & faculty fees$263,22581%
  • Travel & lodging$35,60911%
  • Food & beverage$14,0934%
  • Education$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$324,215 in reported general payments places this provider in the 95th percentile of 44 pulmonary disease providers in Hawaii.

See all pulmonary disease providers in Hawaii

Medicare billing

Part B allowed, 2024
$197,128
Medicare patients
410
Services billed
1,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter716$547,836
OfevNintedanib Esylate18$212,889
TezspireTezepelumab-Ekko30$120,057
Spiriva RespimatTiotropium Bromide100$68,931
Breztri AerosphereBudesonide/Glycopyr/Formoterol98$67,046
Breo ElliptaFluticasone/Vilanterol82$35,959
Arnuity ElliptaFluticasone Furoate63$27,296
EliquisApixaban39$24,307
XareltoRivaroxaban23$24,080
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$21,071
Combivent RespimatIpratropium/Albuterol Sulfate27$18,869
Incruse ElliptaUmeclidinium Bromide29$15,205
SymbicortBudesonide/Formoterol Fumarate52$14,782
Advair HfaFluticasone Propion/Salmeterol30$12,790
Wixela InhubFluticasone Propion/Salmeterol87$10,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta$205,258$655,257953 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$48,122$300,689145 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$54,512$201,885180 claims
PfizerEliquis$48$24,30739 claims
Johnson & JohnsonXarelto$642$24,08023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 pulmonary disease providers in Hawaii.

Other pulmonary disease in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →